Home Shop Science About View Cart →
Home › Fat Loss › Tirzepatide
Dual Agonist · SubQ 99%+ Purity Tirzepatide
Fat Loss Most Popular

Tirzepatide

Tirzepatide — dual GIP/GLP-1 agonist that outperforms single-axis GLP-1 therapy for fat loss and metabolic remodelling.

★★★★☆ 4.7 · 74 verified reviews · See all
Price range: $30.00 through $320.00
Clear
🚚 Free expedited shipping on orders over $100 CAD · Estimated delivery: 2–4 business days
🔬 Third-Party Tested
🇨🇦 Ships Canada-Wide
📦 Discreet Packaging
🛡 Satisfaction Guarantee
Key Benefits
  • Activates both GIP and GLP-1 receptors — broader metabolic coverage than GLP-1 alone
  • Clinically demonstrated 20-22% body weight reduction at maximum dose
  • Significantly improves insulin sensitivity and HbA1c beyond GLP-1 monotherapy
  • Reduces visceral adipose tissue and ectopic fat deposition
  • Weekly injection with sustained appetite suppression throughout the dosing interval
Community Insights

Why people research Tirzepatide

These are the specific situations and goals that lead researchers to Tirzepatide. For research purposes only.

01
Breaking a hard weight loss plateau after months of stalling on semaglutide
02
Eliminating residual food cravings that semaglutide reduced but didn't fully silence
03
Reaching a genuinely lean physique
not just losing 20 lbs for health but hitting a body composition goal
04
Treating insulin resistance without a formal diabetes diagnosis when GLP-1 mono-therapy wasn't enough
05
Getting off blood pressure or cholesterol medications through weight loss and direct metabolic effects
06
Managing dramatic blood sugar swings and energy crashes that drive binge eating
07
Achieving superior glycaemic control for Type 2 diabetes compared to semaglutide
08
Preventing fat rebound while coming off a TRT cycle
09
Losing weight for a hard deadline
wedding, surgery, reunion — choosing tirzepatide for its higher mean weight loss numbers
10
Targeting binge eating episodes that persisted on semaglutide mono-therapy
Protocol Builder

Dosage Calculator

Reference dosing by experience level. For research use only — always consult a licensed healthcare provider.

Suggested Dose
—
Select experience level and click Show Protocol
Reconstitution Guide
—
Based on 10mg vial + 2mL BAC water
Suggested Cycle Length
12–24 weeks
For research reference only

⚠ For research reference only. Tirzepatide is not approved for human use. Always consult a qualified healthcare professional.

In Every Order

What's in the Box

Every Poptides order arrives in premium packaging, ready to use.

💊

Tirzepatide Vial

Your selected amount of lyophilized Tirzepatide in a sealed, sterile glass vial with silver crimp cap. COA included on request.

💧

BAC Water 3mL

Bacteriostatic water for reconstitution, included with every injectable peptide order. Maintains sterility for multi-dose use.

💉

Syringe Kit

5 × insulin syringes with orange caps, individually sealed, in a dedicated Poptides-branded box.

📋

Research Guide Card + Thank You Note

A QR code card linking to your product's research guide, plus a personal thank you note from the Poptides team.

📦

Discreet Outer Packaging

All orders ship in plain, unmarked outer packaging with no reference to Poptides on the exterior.

Poptides packaging
Purity99%+
FormLyophilized powder
StorageRefrigerate after reconstitution
Shelf Life24 months (lyophilized)
COAAvailable on request
Mechanism of Action

How Tirzepatide Works

The mechanism of action, step by step.

01

Dual Receptor Activation

Tirzepatide acts as a co-agonist at both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, engaging two distinct hormonal pathways simultaneously for additive metabolic benefit.

02

Enhanced Adipose Lipolysis

GIP receptor activation in adipose tissue directly promotes fatty acid release and oxidation, a mechanism absent in GLP-1-only agents and responsible for tirzepatide's superior fat loss outcomes.

03

Superior Insulin Sensitisation

The combined GIP/GLP-1 signal improves peripheral insulin sensitivity at the muscle and liver level to a greater degree than GLP-1 agonism alone, reducing fasting and postprandial glucose.

04

Central Appetite Suppression

Hypothalamic and brainstem GLP-1R engagement reduces appetite-driving neural circuits, while GIP receptor signalling in reward-related regions may further blunt hedonic eating.

Dosing Protocols

Research Protocol

Published preclinical dosing guidelines for reference.

Starting Dose
2.5 mg
Once weekly for 4 weeks
Maintenance
5–15 mg
Titrate by 2.5 mg every 4 weeks
Max Dose
15 mg
Higher doses show greater effect in trials
Titration
4–20 weeks
Slow escalation reduces GI side effects
Active Phase
6–18 months
Sustained weight loss continues
Reassessment
Every 3 months
Monitor metabolic markers with clinician
Peer-Reviewed Research

The Science Behind It

Peer-reviewed research supporting the mechanism of Tirzepatide.

1

Tirzepatide once weekly for treatment of obesity (SURMOUNT-1)

Participants on tirzepatide 15 mg achieved 20.9% mean weight reduction at 72 weeks versus 3.1% on placebo, with 57% of participants losing at least 20% of body weight.

New England Journal of Medicine, 2022
2

Tirzepatide versus semaglutide for weight loss in adults with obesity (SURMOUNT-5)

In a head-to-head comparison, tirzepatide produced 47% greater relative weight loss than semaglutide 2.4 mg at 72 weeks, establishing its superiority as a single-agent metabolic therapy.

New England Journal of Medicine, 2025
3

Dual GIP and GLP-1 receptor agonism and adipose tissue remodelling

Tirzepatide produced preferential reduction in visceral and ectopic fat compared to GLP-1 monotherapy, associated with superior improvements in insulin sensitivity and liver fat content.

Cell Metabolism, 2023
Verified Purchases

Customer Reviews

Verified purchases from Canadian customers.

4.7
★★★★☆
Based on 3 reviews
5★
67%
4★
33%
3★
0%
2★
0%
1★
0%
J
James T.
Edmonton, AB · Weight Loss
★★★★★
✓ Verified Purchase
Better than semaglutide for me

Tried semaglutide for 6 months with decent results. Switched to tirzepatide and the appetite suppression is on another level. Down 31 lbs in 5 months.

M
Michelle C.
Ottawa, ON · Metabolic Health
★★★★★
✓ Verified Purchase
The results are unreal

My endocrinologist pointed me to the SURMOUNT data and I decided to try it for research. 3 months in and the visceral fat reduction is visible. Energy is up significantly.

R
Ryan O.
Winnipeg, MB · Weight Loss
★★★★☆
✓ Verified Purchase
Start slow — worth the patience

First 4 weeks at 2.5 mg were uncomfortable but manageable. By month 2 I was feeling great. Down 18 lbs and the cravings are basically gone.

Common Questions

Frequently Asked Questions

Tirzepatide adds GIP receptor agonism to GLP-1 activity, targeting two distinct hormonal pathways. In head-to-head trials it produces approximately 47% greater relative weight loss than semaglutide 2.4 mg, making it the most effective approved agent in its class.
The highest dose studied in trials is 15 mg weekly. Greater weight loss is observed at higher doses, but so are GI side effects — slow titration starting at 2.5 mg is strongly recommended.
Appetite reduction is typically noticeable within the first 1-2 weeks. Meaningful scale changes appear by weeks 8-12, with peak effects developing over 6-12 months of consistent use.
Yes. Cagrilintide (an amylin analogue) shows additive satiety effects when combined with GLP-1/GIP agonists. 5-Amino-1MQ addresses complementary metabolic pathways (NNMT/NAD+) and is a common stack.
Nausea, diarrhoea, and reduced appetite are most common during titration. These generally resolve within 4-6 weeks of reaching a stable dose. Injecting at bedtime can help manage acute nausea.
Yes — tirzepatide is the active compound in both branded medications. Poptides supplies pharmaceutical-grade tirzepatide for research purposes.
Tirzepatide Tirzepatide
Price range: $30.00 through $320.00